Drug intelligence / Profile preview

long-acting amylin DACRA #2

Development stage: Preclinical
Lead developer: i2o Therapeutics
Modality: Peptides
Administration: Oral

Overview

Long-acting amylin DACRA #2 is a dual amylin and calcitonin receptor agonist (DACRA) being developed by i2o Therapeutics for the treatment of obesity and cardio-renal-metabolic diseases. The drug is designed to activate both the amylin and calcitonin receptor pathways, which play critical roles in appetite suppression, gastric emptying, and glucose metabolism. By utilizing i2o's proprietary oral delivery technology, this long-acting peptide formulation aims to provide a more convenient alternative to injectable metabolic therapies while maintaining potent efficacy in weight loss and metabolic health.

Other names: Dual Amylin and Calcitonin Receptor Agonist #2

Targets

CALCR (Calcitonin receptor)AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on long-acting amylin DACRA #2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on long-acting amylin DACRA #2.

Explore the full profile